Alzheimer Disease
Conditions
Keywords
GV1001, Alzheimer Disease
Brief summary
This clinical study is designed as a multi-center, randomized, double-blind, placebo-controlled, parallel design, prospective, phase II clinical trial. An eligible subject who meets inclusion and exclusion criteria is randomly assigned to three groups: study group 1 (GV1001 0.56 mg), study group 2 (GV1001 1.12 mg) or placebo group. A randomized subject is administered either GV1001 or placebo in a total of 14 times and will be evaluated for the efficacy and safety at week of 24.
Detailed description
GV1001 0.56 mg, 1.12 mg or placebo is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times. 1. Control group (placebo): 30 subjects 2. Study group 1 (GV1001 0.56 mg): 30 subjects 3. Study group 2 (GV1001 1.12 mg): 30 subjects.
Interventions
DRUGNormal Saline 0.9%
Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
DRUGGV1001 0.56 mg
GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
DRUGGV1001 1.12 mg
GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
Sponsors
GemVax & Kael
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. 55 to 85 years of age 2. A patient who satisfies diagnostic criteria for dementia in DSM-IV 3. Probable Alzheimer's disease in NINCDS-ADRDA 4. K-MMSE ≤ 19 at screening and randomization visit 5. GDS 5\ 6 stage 6. MRI or CT scan within 12 months prior to screening visit that proves Alzheimer's disease without any other disease that may cause dementia 7. A patient taking stable doses of donepezil for more than 3 months before screening visit 8. A patient who are able to visit a hospital (including inpatient and outpatient based) and receive cognitive and other tests 9. A patient with a caregiver who can accompany all visits and supervise the subject's compliance with the procedures and study drug prescribed in the protocol, and provide detailed information about the patient 10. Written informed consent by a patient or legal representative
Exclusion criteria
1. Any other cause of dementia shown by CT / MRI findings and neurological examination within 12 months of screening visit * Possible, probable or definite vascular dementia according to the NINDS-AIREN * Other central nervous system diseases that may cause cognitive impairment (cerebrovascular disease including cerebrovascular dementia, Parkinsonism, Huntington's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease, etc.) * Neurological deficits such as delusions, delirium, epilepsy 2. Vitamin B12, folic acid, syphilis serology, and thyroid stimulating hormone (TSH) results are thought to contribute to the severity of dementia or cause dementia 3. A patient who are considered ineligible for this study by investigator due to concurrent or history of significant psychiatric conditions (eg. schizophrenia or bipolar affective disorder) 4. A patient with a history of known or suspected seizures including febrile seizures, a history of significant head trauma with loss of consciousness or recent unconsciousness that is not explained 5. A patient with acute or unstable cardiovascular disease, active peptic ulcer, uncontrolled hypertension, uncontrolled diabetes or insulin dependent patients or any medical condition that may interfere with the completion of clinical trials 6. Hypersensitivity to investigational medicinal products 7. History of alcohol, substance abuse or dependence (except nicotine dependence) within the last 2 years 8. Concurrent malignancies or invasive cancers diagnosed within the past 5 years except for non-metastatic basal cell carcinoma or squamous cell carcinoma of skin, in situ carcinoma of the uterine cervix or non-metastatic prostate cancer 9. Renal impairment (creatinine clearance (CLcr) \<30 mL / min) 10. Severe liver dysfunction (ALT or AST\> 2 times the upper limit of normal) 11. A patient taking other drugs other than donepezil to treat Alzheimer's disease or other cognitive impairment 12. A patient taking other drugs other than anticholinergic drugs, cholinergic drugs (local usages are allowable, such as pilocarpine eye drops), antidepressants (tricyclic antidepressant, MAO inhibitor) antipsychotics, donepezil to treat Alzheimer's disease 13. Women at childbearing age who do not consent using medicinally acceptable contraception (such as surgical sterilization, intrauterine contraceptive device, condom or diaphragm, an injectable or inserted contraceptive) during the study 14. Pregnancy or breast feeding 15. A patient who participated in other clinical trials within 4 weeks prior to this study 16. 35 kg weight or below 17. A patient who had experienced this study drug 18. A patient who had participated in a clinical trial for Alzheimer dementia vaccine within last 6 months 19. Any other patients who are considered to be ineligible for this study by an investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SIB (Severe Impairment Battery) | week 24 | Change in SIB compared to the baseline and week 24 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CDR-SOB (Clinical Dementia Rating-Sum of Box) | week 24 | Change in CDR-SOB compared to the baseline and week 24 |
| NPI (Neuropsychiatric Inventory) | week 24 | Change in NPI compared to the baseline and week 24 |
| K-MMSE (Korean-Mini-Mental State Examination) | week 24 | Change in K-MMSE compared to the baseline and week 24 |
| ADCS-ADL-severe (Alzheimer's Disease Cooperative Study-Activities of Daily Living scale-severe) | week 24 | Change in ADCS-ADL-severe compared to the baseline and week 24 |
| CIBIC-plus (Clinician Interview-Based Impression of Change-Plus) | week 24 | Change in CIBIC-plus compared to the baseline and week 24 |
| GDS (Global Deterioration Scale) | week 24 | Change in GDS compared to the baseline and week 24 |
Countries
South Korea
Outcome results
None listed